Condition: B-cell Acute Lymphoblastic Leukemia · B Lineage Lymphoblastic Lymphoma · Sponsor: Stephan Grupp MD PhD
This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).
This description comes directly from the study's public registry record.
CART Nurse Navigator · 445-942-5891 · CARTNurseNavigator@chop.edu
Melissa S. Varghese, M.S. · 8455535358 · varghesem@chop.edu
Always discuss trial participation with your own doctor first.
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05674175